www.med-art.com
The Wall Street Journal (1/16, B3, Rockoff,
Subscription Publication, 2.29M) reports that Wednesday marks the start of a
series of talks that Bristol-Myers Squibb Co. has scheduled in an effort to
settle personal-injury claims related to its hepatitis C drug candidate, 094.
Although BMS has not provided details, the Journal says that persons with
knowledge of the matter, as well as court documents, indicate that the New York
City-based pharmaceutical firm is facing claims, amounting to more than $500
million, for the injuries and one death that occurred last year during
company-sponsored clinical trials to test the treatment in patients with
hepatitis C.
No comments:
Post a Comment